AbbVie’s ABBV mid-stage studies of emraclidine for schizophrenia failed to meet their primary endpoint. Shares of the company ...

AbbVie said a recently acquired drug candidate for schizophrenia missed the key goal in mid-stage studies, pushing its stock ...

Anthony Scaramucci thinks there's a chance that stocks crash. Here's why he's concerned and why a major market collapse is ...

Super Micro settled for $17.5 million, in addition to a $2.1 million clawback from its CEO Charles Liang, who had to ...

After spinning its tires for nearly a decade, is it finally time to pull over and walk away from Ford as a long-term ...